ID   CTC-3
AC   CVCL_YI80
SY   Circulating Tumor Cell-3
DR   CCRID; 4201PAT-CCTCC01209
DR   Wikidata; Q93459979
RX   Patent=CN108611322B;
RX   PubMed=31762819;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201892.
CC   Population: Chinese.
CC   Omics: Transcriptomics; RNAseq.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): PubMed=31762819
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 12,14
ST   D16S539: 11
ST   D21S11: 30,33
ST   D5S818: 11,15
ST   D7S820: 7,10
ST   TH01: 7
ST   TPOX: 11
ST   vWA: 17,18
DI   NCIt; C4872; Breast carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   42Y
CA   Cancer cell line
DT   Created: 19-12-19; Last updated: 10-04-25; Version: 8
//
RX   Patent=CN108611322B;
RA   Zou, Chang
RA   Zhao, Pan
RA   Zhou, Wen-Bin
RA   Wang, Jian-Hong
RT   "Breast cancer circulating tumor cell line CTC-3, culture medium, and
RT   establishment method and application of CTC-3.";
RL   Patent number CN108611322B, 11-Feb-2020.
//
RX   PubMed=31762819; DOI=10.7150/jca.33157; PMCID=PMC6856591;
RA   Zhao, Pan
RA   Zhou, Wen-Bin
RA   Liu, Chang
RA   Zhang, Hui-Rong
RA   Cheng, Zhi-Qiang
RA   Wu, Wei-Qing
RA   Liu, Kai-Sheng
RA   Hu, Hong
RA   Zhong, Cai-Neng
RA   Zhang, Ya-Yuan
RA   Zhou, Dong-Xian
RA   Liu, Fei-Yuan
RA   Dai, Yong
RA   Wang, Jian-Hong
RA   Zou, Chang
RT   "Establishment and characterization of a CTC cell line from peripheral
RT   blood of breast cancer patients.";
RL   J. Cancer 10:6095-6104(2019).
//